Member Info for chester18

At the last SCOPE update 13 patients had reached their scan and the data showed that 11 of those 13 had a response.

Does anyone know or could make a decent guess as to how many patients are likely to have reached the scan / data readout by the end of March ?

I know we won’t be anywhere near the 27 out of 34 goal line but could that figure be over 20 patients by then ?

Hi Violindog

There will be a milestone payment when GenMab have approval to begin a Phase1 Trial.

I know where you are coming from as Lindy did say that the larger milestones come at the backend of the deal.

I do think that there will be news concerning GenMab quite soon, where quite soon means by May or June this year.

A Haribo rocket….

‘Oh he of little faith’

If he does get a whiff of the SP increasing he will definitely give us the benefit of his wisdom. Can’t wait, it will be a sign of good things to come, like a returning comet.

Hi C11

I agree that the GenMab news has the potential to drop at anytime. Not only a milestone but LD also suggested their enquiry to take on another Mab or Target of.

We have the 6 month evaluation from last June meaning that is also a potential next news candidate. From the recent RNS's and news of conference presentations it does look as though we will see reports on both trials early in April.

Lots of potential news by the end of April, how these affect sentiment is anyone's guess but the quality of the data being shared will determine the direction.

My guess is SP in an upwards tragectory. 🤞

If Scancell seek to bring in the £40m or however much it will cost to complete a registration trial, Redmile may stay out of that raising and allow another large investor a seat at the table.

If that came to pass Redmile could convert and hold the shares at a percentage below the mandatory offer threshold.

I've not done any serious calculations rather just putting forward this idea as a possible way Redmile can keep there prominent shareholding and await a much larger deal once registration is either achieved or about to be achieved.

I think BMS are a very strong candidate to acquire Immunobody as a platform if that registration trial successfully completes.

Hi TF

The fact that the title of Lindy's presentation includes a 'MODI1 Update' does suggest that it will include data that is fuller than the brief mention in the January Interim Report.

That's how I read it anyway.

Additional to the late April Conference.

Immuno-Oncology Summit Europe 23rd & 24th April 2024.

Day 1 @ 14.45 Lindy Durrant

'Clinical Update on the DC Targeting Melanoma Vaccine, SCIB1 and Modi1 Vaccine Targeting Citrullination'

My presumption is that this will contain some new data, it doesn't say that it will but 'Clinical Update' is a perfectly good clue for me.

Chester.

Morning Maxparker

As far as I can recall there have not been any promises to update us on any trial data in the first quarter 2024.

However our CEO is presenting at a conference in late April. Please see link attached.

https://www.immuno-oncologyeurope.com/cancer-vaccines

Chester.

There is a very high probability that the Scope trial will continue in a positive way.

Just presuming for a moment that iSCIB+ plus the Doublet of CPI moves forward and successfully completes a Registration Trial.

Our ‘off the shelf’ DNA vaccine plus CPI’s will benefit the vast majority of the estimated 60,000 patients per annum.

Not only a cost effective alternative to personalised therapy’s but also very attractive to health providers like the NHS.

Immunobody will also be proven to be a highly valuable platform.

Chester.

While it feels that news is slow to arrive we must remember that SCIB1 and MODI1 are both at work in their respective patients every day.

Waiting for our next trial update is a challenge but it must be so much harder for the patients currently on our trials to await news of their treatment results.

We do know that there will be updates in April due to our conference heading at the end of that month. The next two months will fly by, Christmas is already 8 weeks in the past.

Chester.

When I considered what could be achieved this year I was thinking more along the lines of chocolate digestives and jaffa cakes piled up at this years AGM. That's what I'd call Shareholder value....... 😄

Chester.

I have followed the journey of SCIB1 from small successful trial in Resected Melanoma to the stalled FDA's clearance of Ichors ‘TriGrid’ device resulting in the change to PharmaJet needle free delivery.

You could argue that around five years were completely wasted and we could be years ahead in the current Scope trial, except for the word ‘But’ !

Three major factors have meant that SCIB1 is exactly bang on time. The FDA holding up the trial with the TriGrid device was actually a blessing as it directly lead to Scancell actively looking for an alternative.

The Pandemic allowed both the PharmaJet delivery and the in human testing of AvidiMab.

The successful rise of Checkpoint Inhibitors and especially their move to first line Standard of Care has opened up SCIB1’s chance to show off an 85% ORR.

Would Redmile have put £40m into a trial that was using Electroploration, I very much doubt it.

The SCIB1 journey has had its twists and turns but it has by this convoluted route ended up at the right time with the right delivery device backed back the right investors.

Chester.

Hi WTP

I think most of us on this board see through any such attempts to create doubt.

To be honest as we begin to receive more data from SCIB1 and Modi1 it would be interesting to see if the doomers pop up even more. A kind of ‘doom mongers’ inverse graph.

Chester.

Hi Desouzaa

The ORR of 85% achieved by Scancell when combined with the two Checkpoint Inhibitors, is amazing. There is no doubt that any other Biotech or Pharma companies in the same space will be very aware of SCIB1.

Currently the number of patients in the reported data is only small but that is being dealt with as each week passes.

If by July 2024 we have treated 35 or 40 patients and the ORR is still well above 70% ( to maintain 85% would be nice ) large Pharma will be extremely interested and the likes of Iovance will be very aware that an ‘off the shelf’ therapy has the potential to push their product to the margins.

We will see data reports by the end of Q3/24 that will have the potential to propel Scancells share price above the most recent high of 29p. The amount and quality of that data could be what I have waited for these past 10 years.

Chester.

Hiya Ray

We have probably discussed the price tag for a commercial SCIB1 + CPI treatment in the past but if it was I cannot remember the details. What would be Scancell's revenue be for a three dose treatment ?

Any rough idea would help me understand the early potential of gaining approval.

If iSCIB+ plus CPI's is successful then I could multiply by 2.5

Chester.

Another unique and groundbreaking cancer treatment now FDA approved and we should wish it every success possible.

This treatment cannot be used on unresectable tumors, here’s a quote from the article :

“ For starters, because Amtagvi is made with TIL cells from a patient’s own tumor, patients with unresectable tumors won’t be eligible for the therapy”.

So Scancell’s SCIB1 + CPI’s is needed just as soon as is humanly possible.

Chester.

Good spot, I'm obviously just checking that everyone is awake ..... 😉

With your permission I will change that to Relative Survival Achievement.

I'm really thinking about the results seen in the original SCIB1 Mono trial. Of the original 16 patients would I be correct in saying that the majority are still alive after 10+ years.

Chester.

At the latest Analyst Presentation Q&A, Lindy said this :

"I think our data is better than Ultimovacs, but I would say that"

Our CEO attests that SCIB1 plus the Doublet of Checkpoints is producing better data. The crux of the results will be around survival expectancy. Will Immunobody plus checkpoints in the SCOPE trial induce memory 'T' Cells and give years of survival rather than months of ?

Chester.

BOJO2020 how can Scancell have let go of an FC.

They are the experts in bonding to the FC region. 😃😃

On the question of what news and when, my thoughts are.

Possible in the next 8 weeks :

Modi1 + CPI Trial Update Early April.

GenMab decision to move to a Phase1 trial with our 'Target'.

Out come of the 6 month Evaluation of GlyMabs by a USA Biotech.

iScib+ 1st Patient Dosed.

Mid Year ( June / July ) :

GenMab to agree another GlyMab or Target of.

A GlyMab deal with other than GenMab.

Neo-Adjuvant Cohort Early Results.

Scib1 + CPI Trial data Update.

Aug / Sept :

Strong Interest in AvidiMab leading to Agreed Evaluation.

iScib+ CPI Trial Initial Update.

Always the chance of some left of field news but all of the above is within the boundaries of what we know or what we have been told.

Chester.